Fundamental studies on physiological and pharmacological actions of L-ascorbate 2-sulfate. V. On the hypolipidemic and antiatherosclerotic effects of L-ascorbate 2-sulfate in rabbits.
Effects of L-ascorbate 2-sulfate (AAS) on lipid metabolism and on pathological changes of aorta and visceral organs were investigated in cholesterol fed rabbits, with ascorbic acid (AA) and clofibrate (CPIB) as reference compounds. Administration of AAS (300 and 150 mg/kg) inhibited an increase in the levels of serum total cholesterol, free cholesterol, triglycerides and phospholipids caused by cholesterol feeding. A high dose of AAS prevented an increase of liver weight. An increase in the level of liver cholesterol was inhibited by a high dose of AAS. Both doses of AAS effectively prevented an accumulation of cholesterol in the aorta. The area rate of atheromatous plaque in aorta was less in specimens from both groups of AAS than in those from control I. Pathological changes in intima and media of aorta were milder in specimens from both groups of AAS. Developed of patholoigcal changes in arteries of various organs were prevented with both doses of AAS.
D000818:Animals; D001013:Aorta, Thoracic / Q000378:metabolism; D001161:Arteriosclerosis / Q000473:pathology / Q000517:prevention & control*; D001205:Ascorbic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology; D000960:Hypolipidemic Agents; D008099:Liver / Q000378:metabolism; D008297:Male; D010743:Phospholipids / Q000097:blood; D011817:Rabbits; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate; D001205:Ascorbic Acid